Full Press Release Details
Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and
in PSVT under review by FDA; PDUFA March 27, 2025
MONTREAL and CHARLOTTE,
N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial
results for the third quarter ended September 30, 2024 and provided a corporate update.
primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,"
said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "We believe that CARDAMYST has the potential
to improve how PSVT is managed and positions Milestone to deliver meaningful value to patients, providers, and payors. Complementing
our efforts in PSVT, we are very encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR which we are working toward
commencing in the first half of 2025."
Quarter and Recent Program Updates
for patients with paroxysmal supraventricular tachycardia (PSVT)
for patients with AFib-RVR
Quarter 2024 Financial Results
further details on the Company's financials, refer to the quarterly report on Form 10-Q for the quarter ended September 30,
2024, filed with the SEC on November 12, 2024.
is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent
and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid response therapy for patients
thereby bypassing the need for immediate medical oversight. If approved, etripamil is intended to provide health care providers with
a new treatment option to enable on-demand care and patient self-management. This portable, self-administered treatment may provide patients
with active management and a greater sense of control over their condition. CARDAMYST (etripamil) nasal spray, the conditionally
approved brand name for etripamil nasal spray, is well studied with a robust clinical trial program that includes a completed Phase 3
clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.
Milestone Pharmaceuticals
Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions
to improve the lives of people living with complex and life-altering heart conditions. The Company's focus on understanding unmet
patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active
role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray
that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe,"
"continue," "could," "demonstrate," "designed," "develop," "estimate,"
"expect," "may," "pending," "plan," "potential," "progress,"
"will", "intend" and similar expressions (as well as other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's
expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties.
Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release
include statements regarding: the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA,
including the timing of the FDA's review of the NDA; the ability of CARDAMYST to improve how PSVT is managed and position Milestone
to deliver meaningful value to patients and providers; the timing of the commercial launch of etripamil for PSVT; and the timing, design
and outcomes of our clinical trials, including our Phase 3 study in AFib-RVR. Important factors that could cause actual results to differ
materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA
will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; whether the FDA will
require additional trials or data which may significantly delay and put at risk our efforts to obtain approval and may not be successful,
the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval
process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks
and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will
validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions,
including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes
in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and
public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional
capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and
Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2023 and its quarterly
report on Form 10-Q for the quarter ended September 30, 2024, under the caption "Risk Factors," as such discussion
may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes
no obligation to update any forward looking statements contained herein to reflect any change in expectations, even as new information
Fox, Vice President, Communications, kfox@milestonepharma.com
Calabrese, ccalabrese@lifesciadvisors.com
Gardner, kgardner@lifesciadvisors.com
Milestone Pharmaceuticals
Condensed Consolidated
Statements of Loss (Unaudited)
of US dollars, except share and per share data)
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | - | $ | - | $ | - | $ | 1,000 | ||||||||
| Operating expenses | ||||||||||||||||
| Research and development, net of tax credits | 3,963 | 6,721 | 10,417 | 25,600 | ||||||||||||
| General and administrative | 3,742 | 4,227 | 12,741 | 12,561 | ||||||||||||
| Commercial | 1,911 | 4,412 | 6,596 | 10,137 | ||||||||||||
| Loss from operations | (9,616 | ) | (15,360 | ) | (29,754 | ) | (47,298 | ) | ||||||||
| Interest income | 1,080 | 1,120 | 3,260 | 2,921 | ||||||||||||
| Interest expense | (903 | ) | (841 | ) | (2,662 | ) | (1,697 | ) | ||||||||
| Net loss and comprehensive loss | $ | (9,439 | ) | $ | (15,081 | ) | $ | (29,156 | ) | $ | (46,074 | ) | ||||
| Weighted average number of shares and pre-funded warrants outstanding, basic and diluted | 66,190,302 | 42,973,160 | 60,856,495 | 42,920,620 | ||||||||||||
| Net loss per share, basic and diluted | $ | (0.14 | ) | $ | (0.35 | ) | $ | (0.48 | ) | $ | (1.07 | ) |
Milestone Pharmaceuticals
Condensed Consolidated
Balance Sheets (Unaudited)
of US dollars, except share data)
| September 30, 2024 | December 31, 2023 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 12,799 | $ | 13,760 | ||||
| Short-term investments | 63,620 | 52,243 | ||||||
| Research and development tax credits receivable | 837 | 643 | ||||||
| Prepaid expenses | 2,523 | 3,178 | ||||||
| Other receivables | 1,211 | 3,208 | ||||||
| Total current assets | 80,990 | 73,032 | ||||||
| Operating lease right-of-use assets | 1,515 | 1,917 | ||||||
| Property and equipment | 201 | 277 | ||||||
| Total assets | $ | 82,706 | $ | 75,226 | ||||
| Liabilities, and Shareholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 4,676 | $ | 6,680 | ||||
| Operating lease liabilities | 582 | 546 | ||||||
| Total current liabilities | 5,258 | 7,226 | ||||||
| Operating lease liabilities, net of current portion | 1,002 | 1,457 | ||||||
| Senior secured convertible notes | 52,434 | 49,772 | ||||||
| Total liabilities | 58,694 | 58,455 | ||||||
| Shareholders' Equity | ||||||||
| Common shares, no par value, unlimited shares authorized 53,327,908 shares issued and outstanding as of September 30, 2024, 33,483,111 shares issued and outstanding as of December 31, 2023 | 288,006 | 260,504 | ||||||
| Pre-funded warrants - 12,910,590 issued and outstanding as of September 30, 2024 and 9,577,257 as of December 31, 2023 | 53,076 | 48,459 | ||||||
| Additional paid-in capital | 38,112 | 33,834 | ||||||
| Accumulated deficit | (355,182 | ) | (326,026 | ) | ||||
| Total shareholders' equity | 24,012 | 16,771 | ||||||
| Total liabilities and shareholders' equity | $ | 82,706 | $ | 75,226 |